Jason Grebely, Marc Bilodeau, Jordan J Feld, Julie Bruneau, Benedikt Fischer, Jennifer F Raven, Eve Roberts, Norma Choucha, Rob P Myers, Selena M Sagan, Joyce A Wilson, Frank Bialystok, D Lorne Tyrrell, Michael Houghton, Mel Krajden
In Canada, hepatitis C virus (HCV) infection results in considerable morbidity, mortality and health-related costs. Within the next three to 10 years, it is expected that tolerable, short-duration (12 to 24 weeks) therapies capable of curing >90% of those who undergo treatment will be approved. Given that most of those already infected are aging and at risk for progressive liver disease, building research-based interdisciplinary prevention, care and treatment capacity is an urgent priority. In an effort to increase the dissemination of knowledge in Canada in this rapidly advancing field, the National CIHR Research Training Program in Hepatitis C (NCRTP-HepC) established an annual interdisciplinary Canadian Symposium on Hepatitis C Virus...
November 2013: Canadian Journal of Gastroenterology